Improvement in vulvar vestibulitis with montelukast.

Abstract

OBJECTIVE:

To determine if montelukast treatment improves symptoms in patients with vulvar vestibulitis.

STUDY DESIGN:

We administered montelukast to a series of patients with vestibulitis seen at the Pennsylvania State University Vulvodynia Clinic over a period of 2.5 years. We reviewed outcomes using a scoring scheme to quantify signs and symptoms, before and after treatment, in 29 montelukast-treated subjects and 18 subjects in a comparison group treated with standard therapies.

RESULTS:

Subjects treated with montelukast showed an average of 52% in improvement in symptoms as compared to a 15% improvement in the controls (p < 0.0001).

CONCLUSION:

Montelukast is a viable treatment option for women with vulvar vestibulitis. This finding implies that leukotrienes have a role in the pathophysiology of vulvar vestibulitis.

• Authors: Neha Kamdar, Laura Fisher, Colin MacNeill
• Journal: The Journal of reproductive medicine (J Reprod Med) Vol. 52 Issue 10 Pg. 912-6 (Oct 2007) ISSN: 0024-7758 [Print] United States
• PMID: 17977165 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Acetates
• Cyclopropanes
• Leukotriene Antagonists
• Quinolines
• Sulfides
• montelukast

Topics

• Acetates (therapeutic use)
• Adult
• Cyclopropanes
• Female
• Humans
• Leukotriene Antagonists (therapeutic use)
• Middle Aged
• Quinolines (therapeutic use)
• Retrospective Studies
• Sulfides
• Treatment Outcome
• Vulvar Vestibulitis (drug therapy)